Payment overview · 2025
General Payments
$674.63
30 reported records · 14 companies
Healthcare provider profile · identity verified
Chawki Gerges, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VISALIA, CA · NPI 1982600946
Verified facts
What the public records show
CMS Open Payments records show Chawki Gerges, M.D. received $674.63 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $236.86 | 35.1% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.86 | 12.3% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $81.20 | 12.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.22 | 7.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.17 | 6.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.25 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.16 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.59 | 3.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.91 | 3.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.91 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.92 | 2.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.00 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.05 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.53 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $632.13 | 29 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $180.10 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.72 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.72 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.86 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $81.20 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $68.75 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 226 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
226 | 52 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2072 | 360 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1587 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 1112 | 193 |
| Lisinopril | Lisinopril | 980 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 956 | 148 |
| Metoprolol Tartrate | Metoprolol Tartrate | 939 | 148 |
| Gabapentin | Gabapentin | 913 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 875 | 198 |
| Furosemide | Furosemide | 782 | 111 |
| Donepezil Hcl | Donepezil Hcl | 749 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 706 | 150 |
| Sertraline Hcl | Sertraline Hcl | 698 | 93 |
| Simvastatin | Simvastatin | 682 | 99 |
| Losartan Potassium | Losartan Potassium | 670 | 109 |
| Metformin Hcl | Metformin Hcl | 644 | 124 |
| Potassium Chloride | Potassium Chloride | 614 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 584 | 115 |
| Clopidogrel | Clopidogrel Bisulfate | 565 | 97 |
| Hydralazine Hcl | Hydralazine Hcl | 551 | 82 |
| Memantine Hcl | Memantine Hcl | 494 | 65 |
| Eliquis | Apixaban | 467 | 80 |
| Carvedilol | Carvedilol | 441 | 74 |
| Trazodone Hcl | Trazodone Hcl | 402 | 72 |
| Omeprazole | Omeprazole | 378 | 63 |
| Ezetimibe | Ezetimibe | 362 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 359 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 348 | 78 |
| Allopurinol | Allopurinol | 344 | 51 |
| Famotidine | Famotidine | 324 | 28 |
| Mirtazapine | Mirtazapine | 318 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 306 | 38 |
| Alprazolam | Alprazolam | 267 | 65 |
| Spironolactone | Spironolactone | 256 | 28 |
| Montelukast Sodium | Montelukast Sodium | 248 | 33 |
| Farxiga | Dapagliflozin Propanediol | 226 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 223 | 55 |
| Azithromycin | Azithromycin | 211 | 177 |
| Jardiance | Empagliflozin | 199 | 33 |
| Tramadol Hcl | Tramadol Hcl | 185 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 25 |
| Januvia | Sitagliptin Phosphate | 179 | 15 |
| Bupropion Xl | Bupropion Hcl | 175 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 39 |
| Valsartan | Valsartan | 160 | 31 |
| Atenolol | Atenolol | 159 | 22 |
| Xarelto | Rivaroxaban | 158 | 23 |
| Enalapril Maleate | Enalapril Maleate | 153 | 32 |
| Midodrine Hcl | Midodrine Hcl | 150 | 25 |
| Meloxicam | Meloxicam | 149 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 60 |
| Glipizide | Glipizide | 146 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 140 | 11 |
| Irbesartan | Irbesartan | 138 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 135 | 21 |
| Ozempic | Semaglutide | 128 | 23 |
| Myrbetriq | Mirabegron | 126 | 16 |
| Cephalexin | Cephalexin | 116 | 79 |
| Oxybutynin Chloride | Oxybutynin Chloride | 116 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 112 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 111 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 28 |
| Finasteride | Finasteride | 104 | 18 |
| Memantine Hcl Er | Memantine Hcl | 99 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 98 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 15 |
| Clonidine Hcl | Clonidine Hcl | 85 | suppressed |
| Celecoxib | Celecoxib | 83 | 21 |
| Prednisone | Prednisone | 83 | 56 |
| Labetalol Hcl | Labetalol Hcl | 82 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 82 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 24 |
| Meclizine Hcl | Meclizine Hcl | 79 | 14 |
| Sucralfate | Sucralfate | 78 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 27 |
| Pregabalin | Pregabalin | 74 | 14 |
| Lorazepam | Lorazepam | 73 | 19 |
| Hydrocortisone | Hydrocortisone | 72 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 71 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 71 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 71 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 68 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 67 | 12 |
| Clonazepam | Clonazepam | 65 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 12 |
| Novolog Flexpen | Insulin Aspart | 62 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 51 |
| Albuterol Sulfate | Albuterol Sulfate | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 59 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | suppressed |
| Synthroid | Levothyroxine Sodium | 59 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 14 |
| Nifedipine Er | Nifedipine | 58 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 56 | 13 |
| Digoxin | Digoxin | 56 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | suppressed |
| Amoxicillin | Amoxicillin | 54 | 45 |
| Ondansetron Odt | Ondansetron | 51 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | 14 |
| Bumetanide | Bumetanide | 49 | 12 |
| Linzess | Linaclotide | 47 | 11 |
| Naproxen | Naproxen | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Baclofen | Baclofen | 44 | 14 |
| Jentadueto | Linagliptin/Metformin Hcl | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Nystatin | Nystatin | 40 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 40 | suppressed |
| Scopolamine | Scopolamine | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 28 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 11 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 13 |
| Estradiol | Estradiol | 32 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Ursodiol | Ursodiol | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 25 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 20 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $674.63 · 30 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AFREZZA, AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error